Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine. II. Results of clinical studies simulating prophylactic therapy for rabies exposure
B. S. Berlin, J. R. Mitchell, G. H. Burgoyne, W. E. Brown and C. Goswick
Rhesus diploid-cell-strain rabies vaccine (RDRV) (adsorbed) is a new rabies
vaccine intended for use in man. Sixty volunteers were given five doses of
RDRV at 0, 3, 7, 14, and 28 days to simulate prophylactic treatment of
persons exposed to a rabid animal. Thirty-five volunteers were given
commercial high-titer rabies immune globulin, 20 IU/kg, before the first
dose of RDRV, and 25 were given RDRV without prior rabies immune globulin.
Antibody responses at 14, 28, and 42 days were comparable with those
reported with human diploid rabies vaccine. Simulated postexposure
prophylactic treatment with RDRV was associated with acceptable levels of
local and constitutional symptoms.
